Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    1(33%)

    Phase Distribution

    Phase 1/2
    3
    100%

    Phase Distribution

    0

    Early Stage

    3

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 1/2Combined phases
    3(100.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    1

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Active(2)
    Other(1)

    Detailed Status

    Not yet recruiting1
    Recruiting1
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    1
    Success Rate
    N/A
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 1/23 (100.0%)

    Trials by Status

    not_yet_recruiting133%
    recruiting133%
    unknown133%

    Recent Activity

    1 active trials
    Showing 3 of 3
    unknownphase_1_2

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

    NCT05280275
    recruitingphase_1_2

    A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

    NCT05573802
    not_yet_recruitingphase_1_2

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

    NCT05581875

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT05280275Phase 1/2

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

    Unknown
    NCT05573802Phase 1/2

    A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

    Recruiting
    NCT05581875Phase 1/2

    A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

    Not Yet Recruiting

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3